Investors
A MESSAGE FROM OUR CEO
“I feel confident that the company now has the right team and plan in place to put SynAct back on the right path.”
-
July 1, 2024 Non RegulatorySynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
-
May 31, 2024 RegulatoryBulletin from the annual general meeting 2024 in SynAct Pharma AB
-
May 31, 2024 RegulatorySynAct Pharma publishes Q1 2024 interim results